新生儿坏死性小肠结肠炎的医学与外科新见解:综述
本综述总结了新生儿坏死性小肠结肠炎(NEC)在微生物组、益生菌、生物标志物、纯人乳喂养及外科管理方面的近期进展。医疗选项基本未变,但对病理生理的理解持续深化,未来靶向预防(如益生菌)和新型生物标志物有望用于高危婴儿。
要点
- NEC治疗仍以支持为主,研究聚焦病理生理与手术时机。
- 纯人乳喂养可能有助于预防NEC,益生菌等靶向预防尚待试验验证。
- 新型生物标志物有望预测病情严重程度及是否需要手术。
核心结论
- NEC医疗选项基本未变,但对其认识不断演进,未来或可常规添加靶向预防措施。
- 新型生物标志物可能有助于预测疾病严重程度或在临床症状出现前识别疾病。
- 持续优化手术结局对需要长期肠外治疗和肠道康复的婴儿至关重要。
研究设计与样本
- 本文为综述,回顾了NEC在微生物组、益生菌、生物标志物、纯人乳喂养及外科管理方面的近期观察。
主要发现
- 综述讨论了微生物组概况和益生菌使用简要回顾。
- 综述讨论了生物标志物未来用于预测疾病进程和手术需要的可能性。
- 综述概述了纯人乳喂养在预防NEC中的效用。
- 综述讨论了NEC外科管理进展,包括手术指征和技术考虑(腹膜引流 vs 剖腹术)。
- 综述总结了接受手术治疗的NEC婴儿的结局。
临床怎么用
- 临床可关注纯人乳喂养作为NEC预防策略。
- 生物标志物未来可能辅助预测NEC病程和手术需求。
- 手术决策需权衡腹膜引流与剖腹术的技术考虑。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Necrotizing enterocolitis (NEC) has long remained a significant cause of morbidity and mortality in neonatal intensive care units. While the mainstay of treatment for this devastating condition remains largely supportive, research efforts continue to be directed toward understanding pathophysiology as well as how best to approach surgical management when indicated. OBSERVATIONS: In this review, we first examine recent medical observations, including overviews on the microbiome and a brief review of the use of probiotics. Next, we discuss the use of biomarkers and how clinicians may be able to use them in the future to predict the course of disease and, perhaps, the need for surgical intervention. We then provide an overview on the use of exclusive human milk feeding and the utility of this approach in preventing NEC. Finally, we discuss recent developments in the surgical management of NEC, beginning with indications for surgery and following with a section on technical surgical considerations, including peritoneal drain vs laparotomy. The review concludes with outcomes from infants with surgically treated NEC. CONCLUSIONS AND RELEVANCE: Although medical treatment options for NEC are largely unchanged, understanding of the disease continues to evolve. As new research methods are developed, NEC pathophysiology can be more completely understood. In time, it is hoped that data from ongoing and planned clinical trials will allow us to routinely add targeted preventive measures in addition to human milk, such as prebiotics and probiotics, to the management of high-risk infants. In addition, the discovery of novel biomarkers may not only prove useful in predicting severity of illness but also will hopefully allow for identification of the disease prior to onset of clinical signs. Finally, continued investigation into optimizing surgical outcomes is essential in this population of infants, many of whom require long-term parenteral therapy and intestinal rehabilitation.
引用
- Frost BL, Modi BP, Jaksic T, et al. New Medical and Surgical Insights Into Neonatal Necrotizing Enterocolitis: A Review. JAMA Pediatr. 2017. PMID: 27893069. doi:10.1001/jamapediatrics.2016.2708
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。